The QTc interval and its dispersion in patients receiving two atypical antipsychotics

European Archives of Psychiatry and Clinical Neuroscience

Volumn 259, Issue 1, 2009, Pages 23-27

  Correll, Christoph U ^a   Frederickson, Anne M ^a   Figen, Vicki ^a   Ginn Scott, Elizabeth J ^a   Pantaleon Moya, Rudy A ^a   Kane, John M ^a   Manu, Peter ^a  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

Atypical antipsychotics; QT dispersion; QT duration; Repolarization

Indexed keywords

AMITRIPTYLINE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; NORTRIPTYLINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOKALEMIA; MALE; MONOTHERAPY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QT DISPERSION; QT INTERVAL; QT PROLONGATION; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART MUSCLE CONDUCTION SYSTEM; LONG QT SYNDROME; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; HYPOKALEMIA; LONG QT SYNDROME; MALE; MIDDLE AGED; RISK FACTORS; SCHIZOPHRENIA;

EID: 65349095163     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-008-0829-4     Document Type: Article

References (14)

1. F Bogun K Kwok Chan M Harvey 1996 QT dispersion in nonsustained ventricular tachycardia and coronary artery disease Am J Cardiol 77 256 259 (Pubitemid 26059293)
2. CU Correll AM Frederickson JM Kane P Manu 2007 Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 89 1-3 91 100 (Pubitemid 44881290)
3. R Ganguly JA Kotzan LS Miller K Kennedy BC Martin 2004 Prevalence, trends, and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenic patients, 1998-2000 J Clin Psychiatry 65 1377 1388
4. PM Haddad IM Anderson 2002 Antipsychotic-related QTc prolongation, torsade de pointes and sudden death Drugs 62 1649 1671 (Pubitemid 34848372)
5. K Hatta T Takahashi H Nakamura 1998 Abnormal physiological conditions in acute schizophrenic patients on emergency admission: dehydration, hypokalemia, leukocytosis and elevated serum muscle enzymes Eur Arch Psychiatry Clin Neurosci 248 180 188 (Pubitemid 28468499)
6. M Joukamaa M Heliovaara P Kneckt 2006 Schixophrenia, neuroleptic medication and mortality Br J Psychiatry 188 122 127
7. SJ Kogut F Yam R Dufresne 2005 Prescribing of antipsychotic medication in a medicaid population: use of polytherapy and off-label dosages J Mang Care Pharm 11 17 24
8. H Koponen K Saari M Savolainen M Isohanni 2002 Weight gain and glucose and lipid metabolism disturbances during antipsychoatic medication: a review Eur Arch Psychiatry Clin Neurosci 252 294 298 (Pubitemid 36227534)
9. P Mackin AH Young 2005 QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: a preliminary study J Clin Psychiatry 66 1386 1391 (Pubitemid 41779536)
10. J Morganroth FV Brozovich JT McDonald 1991 Variability of the QTc measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia Am J Cardiol 67 774 776
11. DM Roden 2006 Long QT syndrome: reduced repolarization reserve and the genetic link J Intern Med 259 59 69
12. JL Waddington HA Youssef A Kinsella 1998 Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study Br J Psychiatry 173 325 329 (Pubitemid 28454819)
13. SW Woods 2003 Chlorpromazine equivalent doses for newer atypical antipsychotics J Clin Psychiatry 64 663 667 (Pubitemid 36750143)
14. AE Yagcioglu BB Akdede TI Turgut 2005 A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety J Clin Psychiatry 66 63 72